Effectiveness of oral ganciclovir on prevention of cytomegalovirus infection after liver transplantation

Pengji Gao,Jie Gao,Zhao Li,Dong Wang,Lei Huang,Zhiping Hu,Jiye Zhu
DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2015.01.007
2015-01-01
Abstract:Objective To investigate the clinical effectiveness of oral ganciclovir on prevention and treatment of cytomegalovirus (CMV) infections after liver transplantation.Method We tested archival peripheral blood of 69 kidney recipients for CYP3A5 genotyping by polymerase chain reaction sequence-specific primer.The dose,blood concentrations and dose-normalized blood concentrations of tacrolimus were measured at 1 st and 2nd month after the renal transplantation.Result pp65 antigen of CMV was negative in all the patients before liver transplantation.In 72 patients subject to acyclovir,9 cases (12.5%) were infected by CMV.By using oral ganciclovir to prevent CMV infection after 1iver transplantation in 376 patients,pp65 antigen of CMV was detected in 17 patients (4.5%).Fifteen patients received intravenous ganciclovir for treatment of CMV infection or CMV pneumonia,and 6 patients (40%) suffered from granulocytopenia because of the use of intravenous ganciclovir.Forty-six patients (12.2%) suffered from granulocytopenia because of the use of oral ganciclovir.Conclusion Oral ganciclovir is a safe and effective drug for prevention and treatment of CMV infection.
What problem does this paper attempt to address?